Postmarketing evaluation of the short-term safety of the pentavalent rotavirus vaccine

Pediatric Infectious Disease Journal

Volumn 31, Issue 3, 2012, Pages 292-296

  Loughlin, Jeanne ^a   Mast, T Christopher ^b   Doherty, Michael C ^c   Wang, Florence T ^a   Wong, Judy ^a   Seeger, John D ^a,c,d  

^a OPTUM   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

immunization; intussusception; Kawasaki disease; rotavirus vaccines

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; ROTAVIRUS VACCINE;

CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG MARKETING; DRUG SAFETY; FEMALE; HEALTH INSURANCE; HUMAN; INFANT; INTUSSUSCEPTION; MAJOR CLINICAL STUDY; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW;

COHORT STUDIES; DRUG TOXICITY; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; INTUSSUSCEPTION; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PROSPECTIVE STUDIES; ROTAVIRUS VACCINES; UNITED STATES; VACCINES, ATTENUATED;

EID: 84857626068     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182421390     Document Type: Review

References (25)

1. Tucker AW, Haddix AC, Bresee JS, et al. Cost-effectiveness analysis of a rotavirus immunization program in the United States. JAMA. 1998;279: 1371-1376.
2. Widdowson MA, Meltzer MI, Zhang X, et al. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics. 2007;119:684-697. (Pubitemid 46556667)
3. Parashar UD, Alexander JP, Glass RI. Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006; 55(RR-12):1-13.
4. Griffin DD, Kirkwood CD, Parashar UD, et al. Surveillance of rotavirus strains in the United States: identification of unusual strains. The National Rotavirus Strain Surveillance System collaborating laboratories. J Clin Microbiol. 2000;38:2784-2787. (Pubitemid 30485175)
5. Abdel-Haq NM, Thomas RA, Asmar BI, et al. Increased prevalence of G1P 4 genotype among children with rotavirus-associated gastroenteritis in metropolitan Detroit. J Clin Microbiol. 2003;41:2680-2682. (Pubitemid 36712490)
6. RotaTeq [package insert]. Whitehouse Station, NJ: Merck and Co, Inc; 2007.
7. Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med. 2001;344:564-572. (Pubitemid 32167870)
8. Chang HGH, Smith PF, Ackelsberg DL, et al. Intussusception, rotavirus diarrhea, and rotavirus vaccine use among children in New York State. Pediatrics. 2001;108:54-60. (Pubitemid 32592005)
9. Eng PM, Mast TC, Loughlin J, et al. Incidence of intussusception among infants in a large insured population of the United States. In: 24th International Conference on Pharmacoepidemiology and Therapeutic Risk Management; August 2008; Copenhagen, Denmark.
10. Vesikari T, Matson DO, Dennehy P, et al. Safety and effectiveness of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354:23-33. (Pubitemid 43048948)
11. CDC. Postmarketing monitoring of intussusception after RotaTeq vaccination- United States, February 1, 2006-February 15, 2007. MMWR. 2007; 56:218-222.
12. Haber P, Patel M, Hector IS, et al. Post-licensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006- September 25, 2007. Pediatrics. 2008;121:1206-1212.
13. Loughlin J, Wang FT, El Khoury A, et al. Adherence to the recommended pentavalent rotavirus vaccine administration schedule in the United States: 2006-2007 [Letter]. Ped Infect Dis J. 2009;28:667-668.
14. Parashar UD, Glass RI. Rotavirus vaccines-early success, remaining questions. N Engl J Med. 2009;360:1063-1065.
15. Parsons LS. Performing a 1:N case-control match on propensity score. SUGI 29, Paper 165. Available at: http://www2.sas.com/proceedings/ sugi29/165-29.pdf.
16. The Brighton Collaboration: Clinical case definition for acute intussusception in infants and children. Available at: http:// brightoncollaboration.org/internet/en/index/working-groups/case-definition- working/completed/intus susception/survey.-MainContentPar-0006-DownloadFile.tmp/ Intus-Webdraft.pdf. Accessed December 13, 2009.
17. Gibbons RV, Parashar UD, Holman RC, et al. An evaluation of hospitalizations for Kawasaki syndrome in Georgia. Arch Pediatr Adolesc Med. 2002;156:492-496. (Pubitemid 34492583)
18. Jennison C, Turnbull BW. Group Sequential Methods With Applications to Clinical Trials. Boca Raton, FL: Chapman and Hall/CRC; 2000:171-187, 235-244.
19. Davis RL, Black S, Shinefield H, et al. Vaccine. 2004;22:536-543.
20. SAS/STAT Software, version 9.1.3. SAS Institute Inc, Cary, NC.
21. STATA Software, release 6. Stata Press. College Station, TX.
22. Brown LD, Cai TT, DasGupta A. Interval estimation for a binomial proportion. Statistica Sci. 2001;16:101-117.
23. Haber P, Patel M, Izurieta HS, et al. Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007. Pediatrics. 2008;121:1206-1212.
24. Belongia EA, Irving SA, Shui IM, et al. Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovinederived rotavirus vaccine. Pediatr Infect Dis J. 2010;29:1-5.
25. Baggs J, Haber P. Continued surveillance for intussusception (IS) following RotaTeq in VAERS and VSD. Presented at: Advisory Committee on Immunization Practices (ACIP); October 28, 2010; Atlanta, GA.